MiMedx reports a $0.05 per share loss for Q2, missing estimates, while revenue of $64M slightly exceeds expectations.
MiMedx Group posted a Q2 non-GAAP loss of $0.05 per share, missing analyst estimates by $0.02. Revenue totaled $64M, a 35.1% year-over-year decline but $0.54M above consensus.
The company’s revenue drop reflects ongoing challenges in its core markets, though the slight beat offers a modest positive. Cash reserves stood at $136 million as of June 30, 2026, down from $166 million previously.
Market reaction to the mixed results remains unclear as trading continues.